— Know what they know.
Not Investment Advice

TLOG OTC

TetraLogic Pharmaceuticals Corporation
1W: +0.0% 1M: +150.0% 3M: +150.0% YTD: +0.0% 1Y: -50.0% 3Y: -98.0% 5Y: -99.7%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 61 · $2447 mcap · 22M float · 0.0000% daily turnover · Short 97% of daily vol

Balance Sheet Trends

Total Assets
$64M -45.9% ▼
4Y CAGR: +40.7%
Total Liabilities
$70M -17.6% ▼
4Y CAGR: +0.4%
Shareholders Equity
-$6M -117.8% ▼
Cash & Investments
$20M -62.0% ▼
4Y CAGR: +7.1%
Total Debt
$28M -2.4% ▼
Net Debt
$13M -18.4% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2011FY2012FY2013FY2014FY2015
— Assets —
Cash$10M$5M$55M$13M$15M
Short-Term Investments$6M$0$0$41M$5M
Cash & ST Investments$16M$5M$55M$54M$20M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$20K$20K$0$2M
Total Current Assets$16M$5M$55M$56M$22M
Property, Plant & Equip.$297K$172K$140K$528K$418K
Goodwill & Intangibles$0$0$0$58M$42M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$54K$54K$54K$3M$57K
Total Non-Current Assets$351K$226K$194K$62M$42M
Total Assets$16M$5M$56M$118M$64M
— Liabilities —
Accounts Payable$834K$1M$1M$1M$412K
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$722K$2M$2M$3M$3M
Total Current Liabilities$3M$3M$5M$5M$4M
Long-Term Debt$0$5M$0$30M$28M
Other Non-Current Liab.$65M$65M$23K$31M$21M
Total Non-Current Liabilities$65M$70M$23K$80M$66M
Total Liabilities$69M$73M$5M$85M$70M
— Equity —
Common Stock$136$135$2K$2K$2K
Retained Earnings-$54M-$70M-$90M-$126M-$176M
Accumulated OCI$0-$65K-$0-$77K-$72K
Total Stockholders Equity-$53M-$68M$51M$33M-$6M
Total Liabilities & Equity$16M$5M$56M$118M$64M
— Key Metrics —
Total Debt$0$5M$0$29M$28M
Net Debt-$10M$244K-$55M$16M$13M
Total Investments$6M$0$0$41M$5M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms